Rules/misleading presentation/US-MIS-001

Untrue information in one part of an ad cannot be cured by truth elsewhere

AI-verifiedblockerBinding lawRaised as a question — a person decides

Rule

If any part of the ad is untrue or misleading, that defect is not cured by an accurate brief summary elsewhere in the ad.

Check

Identify any untrue or misleading claim anywhere in the ad; note that its presence is a violation regardless of accurate information elsewhere.

Escalate when

Whether a specific claim is 'untrue or misleading' requires interpretation.

Where this comes from

21 CFR 202.1(e)(3)(i). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

… complies with the conditions for the labeling exemption contained in § 201.120 and the advertisement contains no claims for the therapeutic safety or effectiveness of the drug. (3) Scope of information to be included; applicability to the entire advertisement. (i) The requirement of a true statement of information relating to side effects, contraindications, and effectiveness applies to the entire advertisement. Untrue or misleading information in any part of the advertisement will not be corrected by the inclusion in another distinct part of the advertisement of a brief statement containing true information relating to side effects, contraindications, and effectiveness of the drug. If any part or theme of the advertisement would make the advertisement false or misleading by reason of the omission of appropriate qualification or pertinent information, that part or theme shall include the appropriate qualification or pertinent information, which may be concise if it is supplemented by a prominent reference on each page to the presence and location elsewhere in the advertisement of a more complet…

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quote is operative regulatory text, not an example, definition, or preamble gloss. It sits under the heading '(3) Scope of information to be included; applicability to the entire advertisement,' and the immediately preceding sentence ('The requirement of a true statement ... applies to the entire advertisement') confirms the paragraph's purpose is exactly the proposition the rule states. Read in context, the source establishes the rule.
- The rule statement tracks the source closely: 'untrue or misleading information in any part' not 'corrected by ... another distinct part ... a brief statement containing true information' maps to 'defect is not cured by an accurate brief summary elsewhere in the ad.' No strengthening of a 'should' into a 'must'; the regulation is mandatory on its face ('will not be corrected'), and nothing is broadened from one medium to all media — (e)(3) is expressly medium-neutral and applies to the entire advertisement, unlike the broadcast-specific provisions in (e)(1)(i)–(ii).
- Atomic: a single proposition (no cross-curing of a defect by accurate content elsewhere). It does not bundle in the separate requirement from the next sentence of (e)(3)(i) (that the offending part or theme must itself carry the appropriate qualification, which may be concise if supplemented by a prominent page-level cross-reference) — correctly left as a distinct rule.
- Determinism 'judgment' is right: the trigger turns on whether content is 'untrue or misleading,' which is an impression/adequacy determination, not a literal match. The escalate-when condition is consistent with this.
- Authority 'binding' is right: 21 CFR 202.1 is a codified FDA regulation, and the cited sentence is regulatory text rather than guidance.
- Locator 21 CFR 202.1(e)(3)(i) is accurate — the quoted sentence is the second sentence of (e)(3)(i) in the source text.
- Severity 'blocker' is defensible: the provision defines when an advertisement fails the section 502(n) 'true statement' requirement, and (e)(5)(i) confirms an advertisement that is false or misleading does not satisfy that requirement — a misbranding-level defect, not a stylistic one.
- applies_when = promotional is justified and not invented: §202.1 governs prescription drug advertisements, which are promotional by definition. The narrower limit (prescription drug advertisements specifically, and the (e)(2) exemptions for reminder, bulk-sale, and prescription-compounding advertisements) is not a practical gap here, since exempt advertisements by definition carry no therapeutic claims that could be untrue or misleading in the relevant sense.
- One nuance checked and found not to be an overstatement: the following sentence of (e)(3)(i) permits a concise qualification with a prominent cross-reference to fuller discussion elsewhere. That does not contradict the check, because the permitted cure requires the qualification to appear in the offending part itself — accurate content elsewhere alone still never cures. The check's 'regardless of accurate information elsewhere' remains accurate as written.

Nearby rules

US-MIS-002